Abcam, ab316930, Anti-TWEAK antibody [EPR28107-36] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TWEAK antibody. Carrier free. Suitable for WB and reacts with Human, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28107-36,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab316930 is the carrier-free version of
ab316929
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4 Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The TNF-like weak inducer of apoptosis (TWEAK) also known as CD255 is a cytokine involved in a variety of cellular processes. This protein has an approximate mass of 24 kDa. TWEAK is expressed in many tissues including the heart brain and spleen. It functions by binding to the fibroblast growth factor-inducible 14 (Fn14) receptor leading to the activation of downstream signaling pathways. TWEAK's role as a ligand places it in the tumor necrosis factor (TNF) superfamily highlighting its involvement in cell death and inflammation signaling.
Biological function summary
TWEAK modulates processes like cell proliferation differentiation and apoptosis. This cytokine affects the immune response and tissue regeneration becoming significant in processes that require tissue remodeling. While acting independently TWEAK does not form part of a larger protein complex. Instead it signals mainly through its exclusive receptor Fn14 on responsive cells triggering cellular responses that influence its biological activities.
Pathways
TWEAK plays an important role in the NF-kB and MAPK signaling pathways. These pathways are important for immune response regulation and cell survival. In these pathways TWEAK closely interacts with TNF receptor-associated factors (TRAFs) which facilitate TWEAK signaling. The connections to pathways involving inflammatory response highlight its significance in maintaining homeostasis within the cellular environment.
TWEAK's activity links to conditions like cancer and rheumatoid arthritis. In cancer excessive TWEAK signaling can contribute to tumor growth and metastasis through its pro-inflammatory and pro-angiogenic effects. In rheumatoid arthritis TWEAK expression relates to joint inflammation and tissue damage where it interacts with proteins like IL-6 and TNF-alpha. These interactions suggest potential therapeutic targets by modulating TWEAK or its signaling partners to treat these diseases.